+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years - 80Years
All Genders
ID07420296

Evaluating Modified Zipper Therapy for Adults with AQP4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder A Multicenter Phase 3 Randomized Trial

Led by Tianjin Medical University General Hospital · Updated on 2026-05-14

198

Participants Needed

1

Research Sites

25 weeks

Total Duration

AI-Summary

What This Trial Is About

This research aims to assess the effectiveness and safety of a new treatment approach called Modified Zipper Therapy for people experiencing acute attacks of Aquaporin-4 antibody-positive Neuromyelitis Optica Spectrum Disorder AQP4-IgG NMOSD. The study compares this novel method, combining high-dose corticosteroids, plasma exchange, and eculizumab, with the standard therapy of corticosteroids and plasma exchange alone. Researchers want to find out if the new therapy improves neurological recovery, including vision and motor function, better than the usual treatment. Participants will be randomly assigned to one of two groups the Modified Zipper Therapy group or the Standard Therapy group. Both groups receive high-dose intravenous corticosteroids and plasma exchange sessions, but the Modified Zipper Therapy group also receives intravenous eculizumab infusions timed around plasma exchange treatments. Plasma exchange involves at least five sessions every other day, exchanging plasma volume to remove harmful substances. Eculizumab dosing includes an initial dose after the first plasma exchange, supplemental doses after subsequent sessions, and maintenance doses following the last session. The corticosteroid treatment starts with high doses and tapers down to a maintenance dose over six months. During the study, participants attend scheduled clinic visits over a 24-week follow-up period. Assessments include visual acuity tests with various charts, neurological evaluations using disability scales, optical coherence tomography, visual evoked potential tests, and MRI scans of the optic nerves. Researchers also monitor safety with physical exams, laboratory tests, and ECGs. The main outcomes measured are changes in visual acuity and disability status at baseline and 12 weeks, along with several secondary measures tracked throughout the study.

CONDITIONS

Brief Title

Modified Zipper Therapy for AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder

Research Team

C

Chao Zhang

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here